Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

Enzo scores $7M in patent battle with PerkinElmer

Enzo Biochem picked up a $7 million settlement in its ongoing patent squabble with PerkinElmer, resolving one of its many legal wrangles in life sciences.

Definiens bags $20.4M for tissue diagnostics

Germany's Definiens has raised €15 million ($20.4 million) in new financing to expand into digital tissue diagnostics, planning to use Big Data and image analysis to spot cancers.

Navidea bags expanded FDA nod for Lymphoseek

Navidea Biopharmaceuticals secured the FDA's blessing to market Lymphoseek, its diagnostic aid, for use in head and neck cancer patients.

Enterome teams up with Mayo for gut diagnostics

Paris' Enterome Biosciences has signed a deal with the Mayo Clinic to collaborate on tests that look to the microbiome to predict patient response to obesity treatment.

Natera puts its prenatal know-how toward cancer diagnostics

After finding success using its technology to screen unborn babies for chromosomal problems, Natera is looking to see how well its diagnostic platform can detect and monitor cancer.

Sequenom enlists Quest to help market its prenatal test

Sequenom, a contender in the crowded field of noninvasive prenatal testing, has recruited global giant Quest Diagnostics to expand the market for the company's MaterniT21 Plus system.

$90M later, Apollo rebrands Lap-Band and hopes to best Allergan's efforts

Austin, TX's Apollo Endosurgery traded $90 million for Allergan's under-performing Lap-Band technology last year, and now the company is rolling out a marketing effort of its own, looking to succeed where its forebear struggled.

Survey: Med tech sales reps are out-earning biopharma

Despite shifting reimbursement policies and industrywide pricing pressures, it's a good time to be a medical device sales rep, according to a new survey. The sector's sellers are making more money than their pharma counterparts, MedReps.com reports, and they picked up a 5% raise over last year.

Biosensors picks a new CEO as revenues slide

Singapore medical device outfit Biosensors International is shaking up its boardroom after a tepid financial performance, working to move on from what it deemed "a challenging year."

Sleep apnea startup banks $11M for ultrasmall device development

Belgian-Israeli startup Nyxoah picked up €8 million ($10.9 million) in financing to advance its tiny neurostimulation treatment for obstructive sleep apnea.